A call for evidence-based medical treatment of opioid dependence in the united states and Canada

Health Affairs

Volumn 32, Issue 8, 2013, Pages 1462-1469

  Nosyk, Bohdan ^a,b   Douglas Anglin, M ^c   Brissette, Suzanne ^d   Kerr, Thomas ^b,e   Marsh, David C ^f   Schackman, Bruce R ^g   Wood, Evan ^b,e   Montaner, Julio S G ^b,e  

^a SIMON FRASER UNIVERSITY   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; DIHYDROCODEINE; HYDROMORPHONE; ILLICIT DRUG; METHADONE; MORPHINE; NALOXONE; NALTREXONE; OPIATE; PRESCRIPTION DRUG;

ARTICLE; CANADA; CLINICAL PRACTICE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CRIMINAL JUSTICE; DROWSINESS; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG FORMULARY; DRUG FORMULATION; DRUG IMPLANT; DRUG SAFETY; EVIDENCE BASED PRACTICE; FINANCIAL DEFICIT; HEADACHE; HEALTH CARE POLICY; HEALTH INSURANCE; HEART BEAT; HEROIN DEPENDENCE; HUMAN; LIBIDO DISORDER; LIVER DISEASE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PRESCRIPTION; PUBLIC HEALTH PROBLEM; RELAPSE; SIDE EFFECT; STOMACH PAIN; SUBSTITUTION THERAPY; SWEAT GLAND DISEASE; UNITED STATES;

COST OF HEALTH CARE; FINANCING HEALTH CARE; HEALTH ECONOMICS; HEALTH REFORM; MENTAL HEALTH/SUBSTANCE ABUSE;

ANALGESICS, OPIOID; CANADA; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEALTH SERVICES ACCESSIBILITY; HEROIN DEPENDENCE; HUMANS; INSURANCE COVERAGE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PHYSICIANS' OFFICES; UNITED STATES;

EID: 84884218515     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0846     Document Type: Article

References (58)

1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health [Internet]. Vol. 1: Summary of national findings. Rockville (MD): SAMHSA; 2010 Sep [cited 2013 Jun 27]. Available from: http://www.samhsa.gov/data/2k9/2k9Resultsweb/web/2k9results.pdf
2. Canadian Centre on Substance Abuse. Injection drug users overview [Internet]. Ottawa (ON): CCSA; [modified 2011 May 26; cited 2013 Jul 3]. Available from: http://www.ccsa.ca/Eng/Topics/Populations/IDU/Pages/InjectionDrugUsersOverview.aspx
3. Webster PC. Medically induced opioid addiction reaching alarming levels. CMAJ. 2012;184(3):285-6.
4. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA. 2011;305(13): 1346-7.
5. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7): 1318-27.
6. Centers for Disease Control and Prevention. Home and recreational safey: unintentional poisoning [Internet]. Atlanta (GA): CDC; [last updated 2013 Jul 2; cited 2013 Jun 27]. Available from: http://www.cdc.gov/Homeand RecreationalSafety/Poisoning/index.html
7. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181(12): 891-6.
8. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4): 321-9.
9. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev. 2003;(3): CD002208.
10. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008; (2):CD002207.
11. Nosyk B, Macnab YC, Sun H, Fischer B, Marsh DC, Schechter MT, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol. 2009;170(6):783-92.
12. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32-51.
13. D'Aunno T, Pollack HA. Changes in methadone treatment practices: results from a national panel study, 1988-2000. JAMA. 2002;288: 850-6.
14. Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O'Connor PG, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007; 22(4):527-30.
15. Volkow ND, Montaner J. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff(Millwood). 2011;30(8):1411-9.
16. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Eng J Med. 2011; 365(6):493-505.
17. Alter HJ, Liang TJ. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med. 2012;156(4):317-8.
18. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96(9):1267-78.
19. Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005;14(11):1133-50.
20. Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012; 184(6):E317-28.
21. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the costeffectiveness of methadone maintenance. Am J Public Health. 2000; 90(7):1100-11.
22. Nosyk B, Guh DP, Sun H, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Health related quality of life trajectories of patients in opioid substitution treatment. Drug Alcohol Depend. 2011;118(2-3): 259-64.
23. European Monitoring Centre for Drugs and Drug Addiction. Substitution treatment-treatment regimes [Internet]. Lisbon: EMCDDA; [last updated 2007 Nov 23; cited 2013 Jun 28]. Available from: http://www.emcdda.europa.eu/html.cfm/index41827EN.html
24. Substance Abuse and Mental Health Services Administration. Similarities and differences in opioid treatment programs that provide methadone maintenance or buprenorphine maintenance. N-SSATS Report [serial on the Internet]. 2010 Jan 28 [cited 2013 Jun 28]. Available from: http://www.samhsa.gov/data/2k10/225/225OpiodTx2k10Web.pdf
25. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300(19):2303-5.
26. Gunderson EW, Fiellin DA. Officebased maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs. 2008;22(2): 99-111.
27. Luce J, Strike C. A cross-Canada scan of methadone maintenance treatment policy developments: a report prepared for the Canadian Executive Council on Addictions [Internet]. Ottawa (ON): Canadian Executive Council on Addictions; 2011 Apr [cited 2013 Jun 28]. Available from: http://www.ccsa.ca/ceca/pdf/CECA%20MMT%20Policy%20Scan%20April%202011.pdf
28. Centers for Disease Control and Prevention. Prescription painkiller overdoses: methadone [Internet]. Atlanta (GA): CDC; [last updated 2012 Jul 5; cited 2013 Jun 28]. Available from: http://www.cdc.gov/Features/VitalSigns/Methadone Overdoses/
29. Dasgupta N, Bailey EJ, Cicero T, Inciardi J, Parrino M, Rosenblum A, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010; 11(7):1078-91.
30. Strang J, Hall W, Hickman M, Bird SM. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ. 2010; 341:c4851.
31. American Society of Addiction Medicine. Office-based opioid agonist treatment (OBOT) [Internet]. Chevy Chase (MD): ASAM; 2004 Jul 1 [cited 2013 Jun 28]. Available from: http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policystatements/2011/12/15/officebased-opioid-agonist-treatment-(obot)
32. British Columbia Ministry of Health Services. New PharmaCare coverage for buprenorphine plus naloxone (Suboxonefi) [Internet]. Victoria (BC): The Ministry; 2010 Oct [cited 2013 Jun 28]. Available from: http://www.health.gov.bc.ca/pharmacare/pdf/buprenorphine-plus-naloxonesuboxone-prescriber-pharmacistinfo.pdf
33. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000; 284(13):1689-95.
34. Substance Abuse and Mental Health Services Administration. Medication-assisted treatment for opioid addiction: 2010 state profiles [Internet]. Rockville (MD): SAMHSA; 2011 [cited 2013 Jul 3]. Available from: http://www.dpt.samhsa.gov/pdf/Medication AssistedTreatmentForOpioid Addiction_2010StateProfiles03.pdf
35. Substance Abuse and Mental Health Services Administration. Treatment services (N-SSATS): 2011: data on substance abuse treatment facilities [Internet]. Rockville (MD): SAMHSA; 2012 Nov [cited 2013 Jul 3]. (HHS Publication No. [SMA] 12-4730). Available from: http://www.samhsa.gov/data/DASIS/2k11nssats/NSSATS2011Web.pdf
36. Freedberg SP. Drug users turn death dealers as methadone from Bain hits street. Bloomberg [serial on the Internet]. 2013 Feb 8 [cited 2013 Jun 28]. Available from: http://www.bloomberg.com/news/2013-02-08/drug-users-turn-deathdealers-as-methadone-from-bainhits-street.html
37. Nahra TA, Alexander J, Pollack H. Influence of ownership on access in outpatient substance abuse treatment. J Subst Abuse Treat. 2009; 36(4):355-65.
38. Buck JA. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Aff(Millwood). 2011;30(8):1402-10.
39. O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA. 2005;294(8):961-3.
40. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2004; (4):CD005031.
41. Nosyk B, Marsh DC, Sun H, Schechter MT, Anis AH. Trends in methadone maintenance treatment participation, retention and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J Subst Abuse Treat. 2010;39:22-31.
42. Fairbairn N, Hayashi K, Kaplan K, Suwannawong P, Qi J, Wood E, et al. Factors associated with methadone treatment among injection drug users in Bangkok, Thailand. J Subst Abuse Treat. 2012;43(1):108-13.
43. Substance Abuse and Mental Health Services Administration. Quick statistics from the Drug and Alcohol Services Information System [Internet]. Rockville (MD): SAMHSA; [cited 2013 Jun 28]. Available from: http://wwwdasis.samhsa.gov/webt/tedsweb/tab_year.choose_year_web_table?t_ state=US
44. Kennedy J, Dipzinski A, Roll J, Coyne J, Blodgett E. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend. 2011;114(2-3): 201-6.
45. Nosyk B, Sun H, Evans E, Marsh DC, Anglin MD, Hser YI, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction. 2012;107(9):1621-9.
46. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs shortterm buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008; 300(17):2003-11.
47. Fiellin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA. 2008;300(17):2057-9.
48. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2006;(2): CD002025. Update in: Cochrane Database Syst Rev. 2009;(3): CD002025.
49. Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend. 2010;108(1-2): 110-4.
50. Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304(14):1576-83.
51. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extendedrelease naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011; 377(9776):1506-13.
52. Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction. 2004;99(8):940-5.
53. Krausz M, Verthein U, Degkwitz P, Haasen C, Raschke P. Maintenance treatment of opiate addicts in Germany with medications containing codeine-results of a follow-up study. Addiction. 1998;93(8):1161-7.
54. Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, et al. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat. 2010;38(4):408-11.
55. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011; (12):CD003410.
56. Kerr T, Montaner JS, Wood E. Science and politics of heroin prescription. Lancet. 2010;375(9729): 1849-50.
57. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1-2):83-8.
58. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012; 379(9810):55-70.